Please provide your email address to receive an email when new articles are posted on . The classically defined diffuse subtype of juvenile systemic sclerosis demonstrates more globally severe disease ...

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

DelveInsight’s Diffuse Cutaneous Systemic Sclerosis Market Insightsreport includes a comprehensive understanding of current treatment practices, emerging diffuse cutaneous systemic sclerosis drugs, ...

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...

"Diffuse Cutaneous Systemic Sclerosis Pipeline"As per DelveInsight's assessment, globally, Diffuse Cutaneous Systemic Sclerosis pipeline constitutes 15+ key companies continuously working towards ...

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...

Diffuse systemic sclerosis (dSSc) can be a devastating disease, and to date there are no clearly beneficial treatments. However, the agent relaxin has shown some promise in improving skin disease. [1] ...

Systemic sclerosis, or scleroderma, causes the hardening of skin and connective tissues. Often, the disease harms other organs, such as the heart, kidneys, lungs, and gastrointestinal tract, and it ...

Systemic sclerosis (SSc), also referred to as scleroderma, is a rare autoimmune disease associated with vasculopathy, inflammation, and fibrosis of the skin and/or internal organs. Interstitial lung ...

Although less common than other subtypes of systemic sclerosis (SSc), systemic sclerosis sine scleroderma (ssSSc) makes up more than 8% of SSc cases and "should not be neglected," according to a new ...

(MENAFN- GlobeNewsWire - Nasdaq) The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis ...